<DOC>
	<DOCNO>NCT00000742</DOCNO>
	<brief_summary>Part I : To determine pharmacokinetic dose atevirdine mesylate ( U-87201E ) use combination zidovudine ( AZT ) . To determine pharmacokinetic profile U-87201E AZT 12-week period . Part II : To determine whether decreased viral susceptibility U-87201E develop drug administer concomitantly AZT 12 week . Part III : To evaluate pharmacokinetic effect ddI/AZT/U-87201E therapy ass change viral susceptibility U-87201E . Interest exist development antiretroviral agent possess different mechanism action nucleoside analogs AZT . U-87201E non-nucleoside reverse transcriptase ( RT ) inhibitor demonstrate activity HIV-1 ; however , emerge characteristic non-nucleoside RT inhibitor development rapid resistance HIV isolate . Whether resistance prevent presence nucleoside analogs AZT ddI yet determine .</brief_summary>
	<brief_title>A Phase I Concentration-Controlled Trial Assess Safety , Tolerance , Pharmacokinetics Development Decreased HIV-1 Susceptibility Combination Atevirdine Mesylate ( U-87201E ) , Zidovudine ( AZT ) , Didanosine ( ddI )</brief_title>
	<detailed_description>Interest exist development antiretroviral agent possess different mechanism action nucleoside analogs AZT . U-87201E non-nucleoside reverse transcriptase ( RT ) inhibitor demonstrate activity HIV-1 ; however , emerge characteristic non-nucleoside RT inhibitor development rapid resistance HIV isolate . Whether resistance prevent presence nucleoside analogs AZT ddI yet determine . Part I : Five male patient enter pharmacokinetic concentration-controlled trial U-87201E plus zidovudine University Rochester site . A target plasma concentration range trough U-87201E determine . Pharmacokinetic monitoring continue 7 day desire dose regimen determine . The five patient may eligible continue Part II study complete total 12 week therapy . Part II : At least 10 male patient ( site eligible ) addition five patient Part I receive dos U-87201E determine Part I AZT dose Part I . Therapy administer 12 week . Patients decreased viral susceptibility U-87201E 6 week may offer extension 24 week therapy . Patients follow weekly 8 week every week thereafter end study . Part III : At least eight patient receive 24 week U-87201E/AZT ddI add regimen 12 additional week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Disease Susceptibility</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Atevirdine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : PCP prophylaxis aerosolized pentamidine , trimethoprim / sulfamethoxazole dapsone . Clotrimazole troches nystatin oral suspension oral candidiasis . Acyclovir ( 1000 mg/day ) herpes lesion . Patients must : HIV infection document serologic test HIV culture OR prior diagnosis AIDS establish CDC criterion . CD4 count = &lt; 500 cells/mm3 two evaluation . Part II : No prior therapy antiretroviral immunomodulating agent ( e.g. , AZT , ddI , ddC , interferon ) . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Acute medical problem time study entry ( include active opportunistic infection active cryptococcosis , Pneumocystis carinii , herpes zoster , histoplasmosis , CMV , nonopportunistic disease include liver disease , renal disease , orthostatic hypotension , hypertension , lymphoma ) . Current diagnosis malignancy systemic therapy would require study . Concurrent Medication : Excluded : Any investigational drug . Phenobarbital , phenytoin , ketoconazole , rifampin , cimetidine , beta blocker , chronic antiacid therapy , antiarrhythmic agent medication know affect cardiac conduction seizure threshold . Cytotoxic chemotherapy . Patients follow prior condition exclude : History cardiovascular disease include conduction disturbance , arrhythmia , atherosclerotic heart disease , valvular heart disease . History CNS disease seizure disorder , AIDS Dementia Complex , Progressive Multifocal Leukoencephalopathy , active neurological disorder . History active chronic gastrointestinal disorder chronic diarrhea ( &gt; 4 week duration ) , constipation , unexplained abdominal pain ( irritable bowel syndrome ) , GI motility disorder . History hypercholesterolemia require medication serum cholesterol = &gt; 300 . Part I patient : History inability tolerate zidovudine ( 200 mg q 8 hour ) . Part III patient : History pancreatitis &gt; grade 2 peripheral neuropathy . Prior Medication : Excluded : Cytotoxic chemotherapy within 1 month prior study entry . Part II : prior therapy antiretroviral immunomodulatory agent ( include limit AZT , ddI , ddC , interferon ) . Current use alcohol illicit drug .</criteria>
	<gender>Male</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>